COMP <GO>
CHE vs LLY // FORWARD P/E MULTIPLE
Chemed Corp (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CHE 5
— LLY 10
▲ FORWARD P/E MULTIPLE LEADER: LLY
LAST: $534.72 (-1.33%) • MKT CAP: $7.08B
forward-pe
140.0x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CHE VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CHE | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 32.50% | 83.64% | -51.14 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 23.40% | 32.36% | -8.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.5x | 36.4x | -17.92 | CHE | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 2.30% | +2.30 | CHE | /fcf-yield <GO> |
| Operating Margin | 13.40% | 40.21% | -26.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 31.90% | -31.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 65.30% | 45.51% | +19.79 | CHE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.45% | 0.49% | -0.04 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.68 | 9.29 | +3.39 | CHE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.8 | 77.9 | -16.09 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.51 | +0.57 | CHE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 140.0x | 26.3x | +113.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.08B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CHE REV | LLY REV | CHE GROSS % | LLY GROSS % | CHE FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $65.18B | 32.5% | 83.0% | $325.5M | $16.81B |
| FY 2024 | $1.53B | $45.04B | -3.0% | 81.3% | $368.0M | $8.82B |
| FY 2023 | $1.32B | $34.12B | 44.0% | 79.3% | $271.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CHE // BETA 1.08
LLY // BETA 0.51